138 related articles for article (PubMed ID: 29642211)
1. A case report of sofosbuvir and daclatasvirto treat a patient with acute hepatitis C virus genotype 2 monoinfection.
Li C; Hu J
Medicine (Baltimore); 2018 Apr; 97(15):e0416. PubMed ID: 29642211
[TBL] [Abstract][Full Text] [Related]
2. Satisfactory virological response and fibrosis improvement of sofosbuvir-based regimens for Chinese patients with hepatitis C virus genotype 3 infection: results of a real-world cohort study.
Tao YC; Deng R; Wang ML; Lv DD; Yuan M; Wang YH; Chen EQ; Tang H
Virol J; 2018 Oct; 15(1):150. PubMed ID: 30285800
[TBL] [Abstract][Full Text] [Related]
3. Effect of minor populations of NS5A and NS5B resistance-associated variants on HCV genotype-3 response to daclatasvir plus sofosbuvir, with or without ribavirin.
McPhee F; Hernandez D; Zhou N
Antivir Ther; 2017; 22(3):237-246. PubMed ID: 28008868
[TBL] [Abstract][Full Text] [Related]
4. Real-world effectiveness of daclatasvir plus sofosbuvir and velpatasvir/sofosbuvir in hepatitis C genotype 2 and 3.
Belperio PS; Shahoumian TA; Loomis TP; Mole LA; Backus LI
J Hepatol; 2019 Jan; 70(1):15-23. PubMed ID: 30266283
[TBL] [Abstract][Full Text] [Related]
5. Baseline resistance associated substitutions in HCV genotype 1 infected cohort treated with Simeprevir, Daclatasvir and Sofosbuvir in Brazil.
Aguiar BF; Campos GRF; Rodrigues JPV; Marques NN; Molina BF; Bittar C; Souza FF; Martinelli ALC; Rahal P; Pereira LRL
Clin Res Hepatol Gastroenterol; 2020 Jun; 44(3):329-339. PubMed ID: 31523019
[TBL] [Abstract][Full Text] [Related]
6. Detection of Occult Hepatitis C Virus Infection in Egyptian Patients Who Achieved a Sustained Virologic Response to Direct-Acting Antiviral Agents.
Mashaal AR; Abd El-Hameed M; El Ray AA; Mahmoud Diab T; Dawood RM; Shemis MA; Seyam M
Asian Pac J Cancer Prev; 2022 Sep; 23(9):2965-2971. PubMed ID: 36172658
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of sofosbuvir-based direct-acting antiviral regimens for hepatitis C virus genotype 6 in Southwest China: Real-world experience of a retrospective study.
Wu DB; Jiang W; Wang YH; Chen B; Wang ML; Tao YC; Chen EQ; Tang H
J Viral Hepat; 2019 Mar; 26(3):316-322. PubMed ID: 30380166
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness and safety of daclatasvir/sofosbuvir with or without ribavirin in genotype 3 hepatitis C virus infected patients. Results in real clinical practice.
Margusino-Framiñán L; Cid-Silva P; Mena-de-Cea A; Rodríguez-Osorio I; Pernas-Souto B; Delgado-Blanco M; Pertega-Díaz S; Martín-Herranz I; Castro-Iglesias A
Rev Esp Quimioter; 2019 Apr; 32(2):137-144. PubMed ID: 30761823
[TBL] [Abstract][Full Text] [Related]
9. Viral clearance ameliorates hematological and inflammatory markers among diabetic patients infected with hepatitis C genotype 4.
Abdel Moneim A; Suleiman HA; Mahmoud B; Mabrouk D; Zaky MY; Mahmoud B
Clin Exp Med; 2020 May; 20(2):231-240. PubMed ID: 32076917
[TBL] [Abstract][Full Text] [Related]
10. Acute hepatitis C treatment in advanced renal failure using 8 weeks of pan-genotypic daclatasvir and reduced-dose sofosbuvir.
Goel A; Bhadauria DS; Kaul A; Verma A; Tiwari P; Rungta S; Rai P; Gupta A; Aggarwal R
Nephrol Dial Transplant; 2021 Sep; 36(10):1867-1871. PubMed ID: 33097949
[TBL] [Abstract][Full Text] [Related]
11. Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C patients with genotype-2 infection after completed treatment.
Cheng TS; Liang PC; Huang CF; Yeh ML; Huang CI; Lin ZY; Chen SC; Huang JF; Dai CY; Hsieh PH; Chuang WL; Yu ML
Kaohsiung J Med Sci; 2021 Apr; 37(4):334-345. PubMed ID: 33151016
[TBL] [Abstract][Full Text] [Related]
12. A prospective study of daclatasvir and sofosbuvir in chronic HCV-infected kidney transplant recipients.
Duerr M; Schrezenmeier EV; Lehner LJ; Bergfeld L; Glander P; Marticorena Garcia SR; Althoff CE; Sack I; Brakemeier S; Eckardt KU; Budde K; Halleck F
BMC Nephrol; 2019 Feb; 20(1):36. PubMed ID: 30717681
[TBL] [Abstract][Full Text] [Related]
13. A retrospective study of the efficacy of sofosbuvir plus NS5A inhibitors for patients with hepatitis C virus genotype-2 chronic infection.
Lv DD; Wang ML; Chen EQ; Wu DB; Tao YC; Zhang DM; Tang H
Eur J Gastroenterol Hepatol; 2019 Mar; 31(3):382-388. PubMed ID: 30383554
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of ultra-short, response-guided sofosbuvir and daclatasvir therapy for hepatitis C in a single-arm mechanistic pilot study.
Flower B; Hung LM; Mccabe L; Ansari MA; Le Ngoc C; Vo Thi T; Vu Thi Kim H; Nguyen Thi Ngoc P; Phuong LT; Quang VM; Dang Trong T; Le Thi T; Nguyen Bao T; Kingsley C; Smith D; Hoglund RM; Tarning J; Kestelyn E; Pett SL; van Doorn R; Van Nuil JI; Turner H; Thwaites GE; Barnes E; Rahman M; Walker AS; Day JN; Chau NVV; Cooke GS
Elife; 2023 Jan; 12():. PubMed ID: 36622106
[TBL] [Abstract][Full Text] [Related]
15. Treatment of hepatitis C virus genotype 3-infection.
Pol S; Vallet-Pichard A; Corouge M
Liver Int; 2014 Feb; 34 Suppl 1():18-23. PubMed ID: 24373074
[TBL] [Abstract][Full Text] [Related]
16. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection.
Sulkowski MS; Gardiner DF; Rodriguez-Torres M; Reddy KR; Hassanein T; Jacobson I; Lawitz E; Lok AS; Hinestrosa F; Thuluvath PJ; Schwartz H; Nelson DR; Everson GT; Eley T; Wind-Rotolo M; Huang SP; Gao M; Hernandez D; McPhee F; Sherman D; Hindes R; Symonds W; Pasquinelli C; Grasela DM;
N Engl J Med; 2014 Jan; 370(3):211-21. PubMed ID: 24428467
[TBL] [Abstract][Full Text] [Related]
17. High efficacy of resistance-guided retreatment of HCV patients failing NS5A inhibitors in the real world.
Pérez AB; Chueca N; García-Deltoro M; Martínez-Sapiña AM; Lara-Pérez MM; García-Bujalance S; Aldámiz-Echevarría T; Vera-Méndez FJ; Pineda JA; Casado M; Pascasio JM; Salmerón J; Alados-Arboledas JC; Poyato A; Téllez F; Rivero-Juárez A; Merino D; Vivancos-Gallego MJ; Rosales-Zábal JM; García F;
J Hepatol; 2019 Nov; 71(5):876-888. PubMed ID: 31279901
[TBL] [Abstract][Full Text] [Related]
18. Sofosbuvir-based treatment is safe and effective in Indian hepatitis C patients on maintenance haemodialysis: A retrospective study.
Akhil MS; Kirushnan B; Martin M; Arumugam K; Ganesh Prasad NK; Ravichandran R
Nephrology (Carlton); 2018 May; 23(5):446-452. PubMed ID: 28339162
[TBL] [Abstract][Full Text] [Related]
19. High Efficacy and Safety of Flat-Dose Ribavirin Plus Sofosbuvir/Daclatasvir in Genotype 3 Cirrhotic Patients.
Pellicelli A; Messina V; Giannelli V; Distefano M; Palitti VP; Vignally P; Tarquini P; Izzi A; Moretti A; Babudieri S; Dell'Isola S; Marignani M; Scifo G; Iovinella V; Cariti G; Pompili M; Candilo FD; Fontanella L; Ettorre GM; Vennarecci G; Ippolito AM; Barbarini G
Gut Liver; 2020 May; 14(3):357-367. PubMed ID: 30970444
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of sofosbuvir-based pangenotypic direct-acting antiviral agents for chronic hepatitis C patients without genotype determination: Real-world experience of a retrospective study.
Li J; Wu DB; Jiang W; Chen XB; Xiao GB; Wang YH; Wang ML; Tao YC; Chen EQ
Medicine (Baltimore); 2020 Oct; 99(43):e22726. PubMed ID: 33120769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
